HIV Integrase Inhibitor Solid Forms for Stable Drug Manufacturing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved antiviral agents and methods for treating HIV infections, as well as better methods for preparing and purifying such agents and formulating them into pharmaceutical compositions.
Innovation Solution
The development of crystalline forms, salts, and co-crystals of the HIV integrase inhibitor (7S)-12-hydroxy-1,11-dioxo-N-(2,4,6-trifluorobenzyl)-1,4,5,6,7,11-hexahydro-3H-2,7-methanopyrido[1,2-a][1,4]diazonine-10-carboxamide, which exhibit improved properties such as bioavailability, stability, and manufacturability, through specific crystallization processes and characterization techniques.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If new antiviral agents are developed to treat HIV infections, then therapeutic efficacy is improved, but complexity of drug development and formulation increases
Solution Approach 1:
The patent applies parameter changes by developing multiple solid forms (crystalline forms, salts, co-crystals) of the integrase inhibitor compound. Each solid form represents a different physical or chemical state of the same active ingredient, allowing optimization of therapeutic efficacy, stability, and manufacturability parameters without changing the core molecular structure of the antiviral agent
Solution Approach 2:
The patent employs composite materials through the creation of co-crystals and salt forms that combine the active integrase inhibitor compound with counterions or co-formers. These composite solid forms integrate multiple components into unified structures that provide improved therapeutic properties while maintaining the core antiviral function
2Stability of the object's composition
If crystalline forms are developed to improve stability and bioavailability, then drug performance is enhanced, but manufacturing process complexity increases
Solution Approach 1:
The patent applies preliminary action by pre-establishing multiple stable crystalline forms, salts, and co-crystals of the integrase inhibitor before final drug product development. This advance preparation of various solid forms with characterized stability profiles allows manufacturers to select the most suitable form for their specific manufacturing processes, reducing overall manufacturing complexity
Solution Approach 2:
The patent utilizes phase transitions by developing different solid-state forms (crystalline, amorphous, salt, co-crystal) of the same compound. Each represents a different phase or physical state that can be interconverted or selected based on manufacturing requirements, allowing optimization of both stability and manufacturability through appropriate phase selection
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline forms and salts of the HIV integrase inhibitor provide enhanced therapeutic efficacy, stability, and ease of manufacturing, addressing the challenges of existing antiviral agents in treating HIV infections.
Implementation Method 1
The development of crystalline forms, salts, and co-crystals of the HIV integrase inhibitor... through specific crystallization processes
Data Source
AI summary
The present disclosure relates generally to solid forms of the compound of Formula I:Also disclosed are pharmaceutical compositions comprising said solid forms and methods of making said solid forms. The solid forms of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.